M. Thomas

2.3k total citations · 1 hit paper
27 papers, 1.7k citations indexed

About

M. Thomas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Thomas has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in M. Thomas's work include Lung Cancer Research Studies (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Neuroendocrine Tumor Research Advances (4 papers). M. Thomas is often cited by papers focused on Lung Cancer Research Studies (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Neuroendocrine Tumor Research Advances (4 papers). M. Thomas collaborates with scholars based in United States, Germany and France. M. Thomas's co-authors include G Potron, C Jacquillat, Claude Lesty, G Vaugier, H Piguet, J. Goasguen, Guillaume Dighiero, Gil Tchernia, F Oberling and Ariane Auquier and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

M. Thomas

26 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1981 1.3k citations J L Binet, Ariane Auquier et al. Cancer profile →

Peers

M. Thomas

GENET

PFM

IMMUN

PRM

ONCOL

J L Binet France

C. Portlock United States

Gerardo Musuraca Italy

José Rodríguez Spain

Annarita Conconi Italy

Maura Brugiatelli Italy

Liliana Devizzi Italy

Sharlene Litchy United States

Max Wolf Australia

Seema A. Bhat United States

J L Binet France

M. Thomas

1.9k ×1.5

GENET

1.6k ×1.6

PFM

941 ×1.5

IMMUN

191 ×0.5

PRM

531 ×1.5

ONCOL

Citations per year, relative to M. Thomas M. Thomas (= 1×) peers J L Binet

Countries citing papers authored by M. Thomas

Since Specialization

Citations

This map shows the geographic impact of M. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Thomas more than expected).

Fields of papers citing papers by M. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Thomas. The network helps show where M. Thomas may publish in the future.

Co-authorship network of co-authors of M. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of M. Thomas. A scholar is included among the top collaborators of M. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Thomas. M. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, M., et al.. (2025). Protection of Patients and the Environment Through Optimization of Radiological Safety in Kinshasa Hospitals in the DRC: Proposals for Pedagogical and Didactic Remediation in the Learning Process at Higher and University Levels for the Optimization and Sustainability of Radiation Protection. Journal of Biosciences and Medicines. 13(1). 132–144.

Thomas, M., J.R. Fischer, Stefan Andreas, et al.. (2011). Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7504–7504. 17 indexed citations

Thomas, M., et al.. (2008). Neoadjuvante multimodale Therapie im Stadium IIIA des nicht-kleinzelligen Bronchialkarzinoms^*. DMW - Deutsche Medizinische Wochenschrift. 122(33). 993–998. 1 indexed citations

Thomas, M.. (2005). Cetuximab: Adverse Event Profi le and Recommendations for Toxicity Management. Clinical journal of oncology nursing. 9(3). 332–338. 33 indexed citations

Spigel, David R., John D. Hainsworth, Howard A. Burris, et al.. (2005). Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer. 7(2). 127–132. 25 indexed citations

Greco, F. Anthony, David R. Spigel, Dianna Shipley, et al.. (2005). Bevacizumab and erlotinib in the treatment of patients (pts) with metastatic carcinoma of unknown primary site: A Sarah Cannon Research Institute phase II trial. Journal of Clinical Oncology. 23(16_suppl). 3088–3088. 6 indexed citations

Liggett, William H., John D. Hainsworth, David R. Spigel, et al.. (2005). Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 23(16_suppl). 6556–6556. 3 indexed citations

Hainsworth, John D., Mark Mainwaring, M. Thomas, et al.. (2003). Gefitinib in the Treatment of Advanced, Refractory Non–Small-Cell Lung Cancer: Results in 124 Patients. Clinical Lung Cancer. 4(6). 347–355. 11 indexed citations

Meluch, Anthony A., F. Anthony Greco, James R. Gray, et al.. (2003). Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal. 9(4). 251–260. 92 indexed citations

10.

Thomas, M.. (2003). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Nursing. 26(Supplement 6S). 21S???25S–21S???25S. 15 indexed citations

11.

Thomas, M.. (2002). Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer. Seminars in Oncology Nursing. 18(4 Suppl 4). 20–27. 2 indexed citations

12.

Oelmann, Elisabeth, M. Thomas, Hubert Serve, et al.. (2002). Early Tandem High-Dose Ifosfamide, Carboplatin, Etoposide Therapy with Stem Cell Rescue for Small-Cell Lung Cancer: Brief Report on the Results of a Phase-I/II Trial. Oncology. 63(3). 248–253. 4 indexed citations

13.

Meluch, Anthony A., John D. Hainsworth, J. R. Gray, et al.. (1999). Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.. PubMed. 5(2). 84–91. 40 indexed citations

14.

Hainsworth, John D., Walter J. Urba, Jeremy K. Hon, et al.. (1998). One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. European Journal of Cancer. 34(5). 654–658. 37 indexed citations

15.

Hainsworth, John D., et al.. (1997). 17 Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): A report on 117 patients (PTS) treated by the Minnie Pearl cancer research network. Lung Cancer. 18. 7–7. 3 indexed citations

16.

Mathieu, Emmanuelle, et al.. (1994). La thrombose porte: une complication exceptionnelle de la maladie de Crohn. La Revue de Médecine Interne. 15(9). 589–592. 8 indexed citations

17.

Johnson, David H., Russell F. DeVore, F. Anthony Greco, et al.. (1992). Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.. PubMed. 19(1 Suppl 2). 50–6. 5 indexed citations

18.

Johnson, David H., et al.. (1992). Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.. Journal of Clinical Oncology. 10(2). 292–296. 74 indexed citations

19.

Binet, J L, Ariane Auquier, Guillaume Dighiero, et al.. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48(1). 198–206. 1282 indexed citations breakdown →

20.

Thomas, M.. (1974). Burst Stump Abscess Following Appendicectomy: A Report of Four Cases. Australian and New Zealand Journal of Surgery. 44(1). 47–49. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact